[{"orgOrder":0,"company":"AdvanCell","sponsor":"Morningside","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"212Pb-ADVC001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"AdvanCell","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"AdvanCell \/ Morningside","highestDevelopmentStatusID":"6","companyTruncated":"AdvanCell \/ Morningside"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"212Pb-ADVC001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AdvanCell \/ POINT Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"AdvanCell \/ POINT Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by AdvanCell

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : The collaboration aims on the development of a global 212Pb radioisotope and radioligand supply chain to specifically support the development and commercialization of 212Pb-labeled radioligands including, 212Pb-ADVC001, a best-in-class treatment for meta...

                          Brand Name : 212Pb-ADVC001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 26, 2023

                          Lead Product(s) : 212Pb-ADVC001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Point Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress internal and partnership programs.

                          Brand Name : 212Pb-ADVC001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 23, 2022

                          Lead Product(s) : 212Pb-ADVC001

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Morningside

                          Deal Size : $18.0 million

                          Deal Type : Series B Financing

                          blank